7 results on '"Hissar, Syed"'
Search Results
2. Elucidating the Immune Response to SARS-CoV-2: Natural Infection versus Covaxin/Covishield Vaccination in a South Indian Population.
- Author
-
Vanamudhu, Agalya, Devi Arumugam, Renuka, Nancy, Arul, Selvaraj, Nandhini, Moiden, Kadar, Hissar, Syed, Ranganathan, Uma Devi, Bethunaickan, Ramalingam, Babu, Subash, and Kumar, Nathella Pavan
- Subjects
IMMUNOLOGIC memory ,IMMUNE system ,IMMUNE response ,COVID-19 vaccines ,SARS-CoV-2 Delta variant ,T cells - Abstract
A natural infection or a vaccination can initially prime the immune system to form immunological memory. The immunity engendered by vaccination against COVID-19 versus natural infection with SARS-CoV-2 has not been well studied in the Indian population. In this study, we compared the immunity conferred by COVID-19 vaccines to naturally acquired immunity to SARS-CoV-2 in a South Indian population. We examined binding and neutralizing antibody (NAb) levels against the ancestral and variant lineages and assessed the ex vivo cellular parameters of memory T cells, memory B cells, and monocytes and finally measured the circulating cytokine response. COVID-19 vaccination stimulates heightened levels of IgG antibodies against the original strain of SARS-CoV-2, as well as increased binding to the spike protein and neutralizing antibody levels. This enhanced response extends to variant lineages such as B.1.617.2 (Delta, India), B.1.1.529 (Omicron, India), B.1.351 (Beta, South Africa), and B.1.1.7 (Alpha, UK). COVID-19 vaccination differs from SARS-CoV-2 infection by having increased frequencies of classical memory B cells, activated memory B and plasma cells, CD4/CD8 T cells of effector memory, effector cells, stem cell-like memory T cells, and classical and intermediate monocytes and diminished frequencies of CD4/CD8 T cells of central memory and non-classical monocytes in vaccinated individuals in comparison to those with natural infection. Thus, COVID-19 vaccination is characterized by enhanced humoral responses and robust activation of innate and memory T cell responses in comparison to natural infection in a South Indian population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Efficacy and tolerability of a 4-month ofloxacin-containing regimen compared to a 6-month regimen in the treatment of patients with superficial lymph node tuberculosis: a randomized trial.
- Author
-
Hissar, Syed, Velayutham, Banurekha, Tamizhselvan, Manoharan, Rathinam, Sridhar, Arunbabu, Chinnadurai, Vidhya, Jayanthi Bharathi, Vargunapandian, Gurusamy, Sundararajaperumal, Anandakrishnan, Sivaramakrishnan, Gomathi Narayan, Chelvi, Silambu, Ramesh, Paranchi Murugesan, Arun, Damodharan, Reddy, Sirasanambati Devarajulu, Kumaran, Paramasivam Paul, Kumar, Marimuthu Makesh, Kalaiselvi, Dharuman, Hanna, Luke Elizabeth, Kumar, Hemanth, Gowrisankar, Alagarsamy, and Rajavelu, Ramasamy
- Subjects
- *
EXTRAPULMONARY tuberculosis , *LYMPHADENITIS , *LYMPH nodes , *TUBERCULOSIS , *END of treatment , *CLINICAL trials , *DIRECTLY observed therapy - Abstract
Background: Tuberculosis (TB) lymphadenitis is the most common form of extra-pulmonary TB, and the treatment duration is six months. This non-inferiority based randomized clinical trial in South India evaluated the efficacy and safety of a four-month ofloxacin containing regimen in tuberculosis lymphadenitis (TBL) patients. Methods: New, adult, HIV-negative, microbiologically and or histopathologically confirmed superficial lymph node TB patients were randomized to either four-month oflaxacin containing test regimen [ofloxacin (O), isoniazid (H), rifampicin (R), pyrazinamide (Z) -2RHZO daily/ 2RHO thrice-weekly] or a six-month thrice-weekly control regimen (2HRZ, ethambutol/4RH). The treatment was directly observed. Clinical progress was monitored monthly during and up to 12 months post-treatment, and thereafter every three months up to 24 months. The primary outcome was determined by response at the end of treatment and TB recurrence during the 24 months post-treatment. Results: Of the 302 patients randomized, 298 (98.7%) were eligible for modified intention-to-treat (ITT) analysis and 294 (97%) for per-protocol (PP) analysis. The TB recurrence-free favourable response in the PP analysis was 94.0% (95% CI: 90.1–97.8) and 94.5% (95% CI: 90.8–98.2) in the test and control regimen respectively, while in the ITT analysis, it was 92.7% and 93.2%. The TB recurrence-free favourable response in the test regimen was non-inferior to the control regimen 0.5% (95% CI: -4.8-5.9) in the PP analysis based on the 6% non-inferiority margin. Treatment was modified for drug toxicity in two patients in the test regimen, while one patient had a paradoxical reaction. Conclusion: The 4-month ofloxacin containing regimen was found to be non-inferior and as safe as the 6-month thrice-weekly control regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Clinical Outcomes in Children With Human Immunodeficiency Virus Treated for Nonsevere Tuberculosis in the SHINE Trial.
- Author
-
Chabala, Chishala, Wobudeya, Eric, Zalm, Marieke M van der, Kapasa, Monica, Raichur, Priyanka, Mboizi, Robert, Palmer, Megan, Kinikar, Aarti, Hissar, Syed, Mulenga, Veronica, Mave, Vidya, Musoke, Philippa, Hesseling, Anneke C, McIlleron, Helen, Gibb, Diana, Crook, Angela, Turkova, Anna, and Team, the SHINE Trial
- Subjects
DRUG therapy for tuberculosis ,TUBERCULOSIS mortality ,HIV infection complications ,ANEMIA ,SECONDARY analysis ,LEANNESS ,RESEARCH funding ,VIRAL load ,MALNUTRITION ,HIV-positive persons ,HOSPITAL care ,CD4 lymphocyte count ,HEMOGLOBINS ,HIV infections ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,ANTITUBERCULAR agents ,ODDS ratio ,ANTI-HIV agents ,COMPARATIVE studies ,DISEASE relapse ,ADVERSE health care events ,CONFIDENCE intervals ,CHILDREN - Abstract
Background Children with human immunodeficiency virus (HIV, CWH) are at high risk of tuberculosis (TB) and face poor outcomes, despite antiretroviral therapy (ART). We evaluated outcomes in CWH and children not living with HIV treated for nonsevere TB in the SHINE trial. Methods SHINE was a randomized trial that enrolled children aged <16 years with smear-negative, nonsevere TB who were randomized to receive 4 versus 6 months of TB treatment and followed for 72 weeks. We assessed TB relapse/recurrence, mortality, hospitalizations, grade ≥3 adverse events by HIV status, and HIV virological suppression in CWH. Results Of 1204 children enrolled, 127 (11%) were CWH, of similar age (median, 3.6 years; interquartile range, 1.2, 10.3 versus 3.5 years; 1.5, 6.9; P =.07) but more underweight (weight-for-age z score, −2.3; (3.3, −0.8 versus −1.0; −1.8, −0.2; P <.01) and anemic (hemoglobin, 9.5 g/dL; 8.7, 10.9 versus 11.5 g/dL; 10.4, 12.3; P <.01) compared with children without HIV. A total of 68 (54%) CWH were ART-naive; baseline median CD4 count was 719 cells/mm
3 (241–1134), and CD4% was 16% (10–26). CWH were more likely to be hospitalized (adjusted odds ratio, 2.4; 1.3–4.6) and to die (adjusted hazard ratio [aHR], 2.6; 95% confidence interval [CI], 1.2 to 5.8). HIV status, age <3 years (aHR, 6.3; 1.5, 27.3), malnutrition (aHR, 6.2; 2.4, 15.9), and hemoglobin <7 g/dL (aHR, 3.8; 1.3,11.5) independently predicted mortality. Among children with available viral load (VL), 45% and 61% CWH had VL <1000 copies/mL at weeks 24 and 48, respectively. There was no difference in the effect of randomized treatment duration (4 versus 6 months) on TB treatment outcomes by HIV status (P for interaction = 0.42). Conclusions We found no evidence of a difference in TB outcomes between 4 and 6 months of treatment for CWH treated for nonsevere TB. Irrespective of TB treatment duration, CWH had higher rates of mortality and hospitalization than their counterparts without HIV. Clinical Trials Registration. ISRCTN63579542. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
5. Sex-specific differences in systemic immune responses in MIS-C children
- Author
-
Rajamanickam, Anuradha, primary, Kumar, Nathella Pavan, additional, Venkataraman, Aishwarya, additional, Varadarjan, Poovazhagi, additional, Selladurai, Elilarasi, additional, Sankaralingam, Thangavelu, additional, Thiruvengadam, Kannan, additional, Selvam, Ramya, additional, Thimmaiah, Akshith, additional, Natarajan, Suresh, additional, Ramaswamy, Ganesh, additional, Putlibai, Sulochana, additional, Sadasivam, Kalaimaran, additional, Sundaram, Balasubramanian, additional, Hissar, Syed, additional, Ranganathan, Uma Devi, additional, and Babu, Subash, additional
- Published
- 2024
- Full Text
- View/download PDF
6. Distinct TB-antigen stimulated cytokine profiles as predictive biomarkers for unfavorable treatment outcomes in pulmonary tuberculosis.
- Author
-
Pandiarajan, Arul Nancy, Kumar, Nathella Pavan, Selvaraj, Nandhini, Ahamed, Shaik Fayaz, Viswanathan, Vijay, Thiruvengadam, Kannan, Hissar, Syed, Shanmugam, Sivakumar, Bethunaickan, Ramalingam, Nott, Sujatha, Kornfeld, Hardy, and Babu, Subash
- Subjects
TUBERCULOSIS ,TREATMENT effectiveness ,CYTOKINES ,BIOMARKERS ,IMMUNE response - Abstract
Introduction: The assessment of tuberculosis (TB) treatment outcomes predominantly relies on sputum culture conversion status. To enhance treatment management, it is crucial to identify non-sputum-based biomarkers that can predict unfavorable outcomes. Cytokines are widely studied as diagnostic biomarkers for active TB. However, their potential as indicators for unfavorable treatment outcomes remains uncertain. Methodology: This study was conducted within a well-characterized cohort comprising newly diagnosed patients with drug-sensitive pulmonary TB, confirmed through sputum smear and culture positivity. Our objective was to elucidate the TB antigen-stimulated cytokine profile at pre-treatment and at 2 months into anti-TB treatment (ATT) in patients with unfavorable treatment outcomes (cases, n = 27) in comparison to recurrence-free, microbiologically cured controls (n = 31). Whole blood was stimulated with TB antigens using the QuantiFERON In-tube gold method, and plasma supernatants were subjected to a panel of 14 cytokine measurements. Results: In our study, pre-treatment analysis revealed that eight cytokines (IL-2, IFN-γ, TNF-α, IL-6, IL-10, IL-17A, IL-18, and GM-CSF) were significantly elevated at baseline in cases compared to cured controls, both in unstimulated conditions and following TB antigen (CFP10, ESAT6, and TB7.7) stimulation. A similar pattern was observed at the 2-month mark of ATT, with eight cytokines (IL-2, IL-10, IL-13, IFN-γ, IL-6, IL-12p70, IL-17A, and TNF-α) showing significant differences between the groups. Importantly, no variations were detected following mitogen stimulation, underscoring that these distinctive immune responses are primarily driven by TB-specific antigens. Conclusion: Our findings indicate that individuals with unfavorable TB treatment outcomes display a characteristic cytokine profile distinct from TB-cured patients, even before commencing ATT. Therefore, the levels of specific cytokine pre-treatment and at the 2-month point in the course of treatment may serve as predictive immune markers for identifying individuals at risk of unfavorable TB treatment outcomes, with these responses being predominantly influenced by TB-specific antigens. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Xpert MTB/RIF assay in the diagnosis of pulmonary tuberculosis in children in tertiary care setting in South India.
- Author
-
Velayutham B, Hissar S, Thiruvengadam K, Narayan Sivaramakrishnan G, Subramanyam B, Navaneethapandian P, Reddy D, Nair D, Kannabiran B, Balaji S, Selladurai E, Ganesh J, Aravind MA, Rathinam P, Chellaiah LR, Rose W, Luke Elizabeth H, Sakaya A, Joseph B, Sundaralingam V, Karthikeyan S, Dhanaraj B, Natrajan M, and Swaminathan S
- Subjects
- Humans, Female, Child, Male, India, Child, Preschool, Prospective Studies, Infant, Adolescent, Tuberculosis, Pulmonary diagnosis, Tuberculosis, Pulmonary microbiology, Sensitivity and Specificity, Mycobacterium tuberculosis isolation & purification, Mycobacterium tuberculosis genetics, Sputum microbiology, Tertiary Healthcare
- Abstract
Xpert MTB/RIF is recommended for the diagnosis of tuberculosis (TB) in children. We determined the performance of Xpert MTB/RIF in the diagnosis of pulmonary TB in children. The characteristics of children influencing Xpert MTB/RIF positivity were explored. Children aged <15 years with symptoms suggestive of pulmonary TB were prospectively enrolled from 2013 to 2019. Two sputum/early morning gastric aspirate specimens were collected for examination by smear (fluorescence microscopy), Xpert MTB/RIF, and culture [Mycobacteria growth indicator tube (MGIT)/Lowenstein-Jensen (LJ) medium]. Diagnostic performance of Xpert MTB/RIF was evaluated using LJ and or MGIT culture positivity as the reference standard. Sensitivity, specificity with 95% confidence interval (CI) were calculated. Stratified analysis was done; P < .05 was considered statistically significant. Of the total 1727 enrolled children, 1674 (97%) with complete results for at least one sputum/gastric aspirate sample were analyzed. The sensitivity of Xpert MTB/RIF was 68.5% in sputum and 53.6% in gastric aspirate while the specificity was 99% for both. The sensitivity compared to smear was 68.5% vs. 33.7% (P < .001) and 53.6% vs. 14.5%; (P < .001) in sputum and gastric aspirate, respectively. The sensitivity of Xpert MTB/RIF was 23.9% with decision to treat as reference standard. Xpert MTB/RIF positivity was significantly influenced by sex, age, nutritional status, chest X-ray abnormality, TB infection status, and symptoms suggestive of TB. Xpert MTB/RIF as an upfront test compared to smear improves diagnosis of pulmonary TB in children yet the sensitivity is suboptimal. Newer TB diagnostic tools with improved sensitivity is warranted in children., (© The Author(s) [2024]. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.